SITE011-0239

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-12-09

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-01-31 (study day 44); relationship: not assessed; serious criteria: life-threatening

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-14 (study day 58); relationship: not assessed

severe serious assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-09 (study day 81); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 196); relationship: not assessed

Data queries

No data queries.